Deep Brain Stimulation in India
Get Deep Brain Stimulation at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Deep Brain Stimulation in UAE
Deep Brain Stimulation at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Deep Brain Stimulation (DBS) is a highly specialized neurosurgical procedure that delivers continuous electrical impulses to precisely targeted brain nuclei — most commonly the subthalamic nucleus (STN) or globus pallidus internus (GPi) — to modulate pathological neural circuits responsible for movement disorders, treatment-resistant depression, and obsessive-compulsive disorder. With aggregate motor improvement rates of 60–80% in carefully selected Parkinson's disease patients and durable long-term outcomes documented across decades of peer-reviewed literature, DBS represents the gold standard in functional neurosurgery. GAF Healthcare connects international patients with JCI- and NABH-accredited centers in India and JCI- and DHA-licensed institutions in Dubai and Abu Dhabi, where fellowship-trained functional neurosurgeons and multidisciplinary movement disorder teams deliver this intervention at a fraction of Western costs, with zero compromise on implant quality or programming precision.
Hospital Stay: 5–8 days (including staged lead implantation and initial IPG programming) • Total Stay in Country (Fit-to-Fly): 4–6 weeks (wound healing, device integrity check, and initial stimulation optimization must be completed before long-haul flight clearance) • Success Rate: 70–80% meaningful motor improvement in eligible Parkinson's disease patients; 60–70% responder rate in treatment-resistant OCD (per FDA IDE trial data)
What Is It?
Deep Brain Stimulation addresses neurological and neuropsychiatric conditions rooted in abnormal, hypersynchronized oscillatory activity within the basal ganglia-thalamocortical circuits. In Parkinson's disease, degeneration of dopaminergic neurons in the substantia nigra pars compacta leads to pathological beta-band (13–30 Hz) synchronization in the subthalamic nucleus, manifesting clinically as resting tremor, bradykinesia, rigidity, and postural instability. DBS electrodes implanted in the STN or GPi deliver high-frequency stimulation (typically 130–185 Hz) that disrupts this pathological synchrony, effectively mimicking the functional outcome of a surgical lesion while remaining fully adjustable and reversible. Unlike ablative procedures such as pallidotomy or thalamotomy, DBS preserves tissue integrity and allows clinicians to fine-tune stimulation parameters across the patient's lifetime as disease progression demands.
Beyond Parkinson's disease, DBS has received regulatory approval or Humanitarian Device Exemption (HDE) status for essential tremor (ventral intermediate nucleus of thalamus target), dystonia (GPi target), and obsessive-compulsive disorder (anterior limb of the internal capsule / nucleus accumbens target). Investigational applications include treatment-resistant major depressive disorder (subcallosal cingulate gyrus / Brodmann Area 25 target), Tourette syndrome, epilepsy, and minimally conscious states. The physiological rationale in each indication involves circuit-specific neuromodulation rather than a uniform mechanism, underscoring why precise anatomical targeting — increasingly achieved through 7-Tesla MRI-guided and robotic stereotactic systems — is central to outcome quality.
The contemporary standard of care for DBS demands a multidisciplinary team comprising a movement disorder neurologist, a functional neurosurgeon with dedicated stereotactic training, a neuropsychologist for pre-implant cognitive screening, a DBS programmer (typically an advanced practice provider or clinical neurophysiologist), and a rehabilitation specialist. Leading centers in India and the UAE operate such teams within high-volume programs that perform 50–150+ DBS implantations annually, a case volume associated with significantly superior outcomes in comparative effectiveness research.
Candidates
• ELIGIBLE CONDITIONS: Idiopathic Parkinson's disease with motor fluctuations, dyskinesias, or tremor inadequately controlled by optimized pharmacotherapy (levodopa equivalent daily dose typically >600 mg); Essential tremor refractory to propranolol and primidone; Primary or secondary generalized dystonia; OCD with Y-BOCS score ≥28 despite ≥3 adequate medication trials and intensive CBT; Treatment-resistant depression under compassionate/trial protocols.
• PARKINSON'S DISEASE-SPECIFIC CRITERIA: Confirmed levodopa responsiveness (≥30% UPDRS-III improvement in an acute levodopa challenge); Disease duration ≥4 years; No significant cognitive impairment (MoCA ≥24 preferred; formal neuropsychological battery required); No active psychosis or major untreated depression; No MRI-evident structural lesions at planned target sites.
• REQUIRED PRE-OPERATIVE DIAGNOSTICS: High-resolution 3-Tesla (or 7-Tesla where available) brain MRI with stereotactic sequences for target visualization; Acute levodopa challenge (Parkinson's patients); Comprehensive neuropsychological assessment including MMSE, MoCA, BDI-II, and UPDRS I–IV scoring; Video-recorded OFF-medication and ON-medication motor assessments; Routine pre-surgical investigations: CBC, metabolic panel, coagulation profile (PT/INR/aPTT), ECG, chest X-ray, and anesthesia assessment; Psychiatric evaluation to exclude active psychosis, suicidality, or dementia.
• CONTRAINDICATIONS (ABSOLUTE): Significant cerebral atrophy reducing safe stereotactic access; Active coagulopathy or anticoagulation that cannot be safely bridged; Implanted cardiac devices incompatible with DBS systems (assess case-by-case with cardiologist); MRI-incompatible cardiac pacemakers (unless conditional MRI-safe DBS system selected); Dementia or cognitive impairment that precludes informed participation in programming.
• CONTRAINDICATIONS (RELATIVE): Age >75 years with significant comorbidity index (Charlson ≥4); Poorly controlled hypertension increasing hemorrhagic risk; Active systemic infection; Significant white matter disease on MRI; Unrealistic patient or family expectations — a formal psychosocial suitability assessment by a movement disorder social worker is mandatory.
Procedure
STANDARD DBS IMPLANTATION (FRAME-BASED STEREOTAXY): The historical gold standard involves rigid Leksell or CRW stereotactic frame application under local anesthesia, CT-to-MRI image fusion for target coordinate calculation (STN target coordinates approximately 12 mm lateral, 3 mm posterior, 4 mm inferior to the midcommissural point), and microelectrode recording (MER) during awake craniotomy to electrophysiologically confirm target identity via characteristic STN neuronal firing patterns (irregular, 20–50 Hz discharge with high background activity). A quadripolar or directional octapolar DBS lead (e.g., Medtronic 3389/3387, Abbott Infinity, Boston Scientific Vercise Cartesia) is then implanted and secured. The implantable pulse generator (IPG) — either a primary cell (Medtronic Activa PC/SC) or rechargeable device (Abbott Infinity RC, Boston Scientific Vercise Genus Recharge) — is implanted in the infraclavicular subcutaneous pocket in a second stage, typically 1–7 days later.
FRAMELESS ROBOTIC-ASSISTED DBS (ADVANCED APPROACH): Robotic stereotactic platforms — including the ROSA Brain robot (Zimmer Biomet) and Medtronic's StealthStation with O-arm intraoperative CT — have transformed DBS implantation by enabling frameless, image-guided electrode placement with submillimeter accuracy (reported radial targeting error <1.0 mm). Robots perform automated trajectory planning, collision detection, and real-time fluoroscopic verification, significantly reducing operative time and improving reproducibility. Robotic DBS is increasingly available at premier centers in India (Bengaluru, Chennai, Mumbai, Delhi) and the UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital Dubai), and is particularly valuable for patients who cannot tolerate awake procedures.
ASLEEP DBS WITH INTRAOPERATIVE IMAGING: For patients with severe anxiety, significant OFF-state disability, or pediatric dystonia, asleep DBS under general anesthesia combined with intraoperative MRI (iMRI) or intraoperative CT (iCT) verification provides equivalent lead accuracy to awake MER-guided techniques in published comparative series. iMRI suites (e.g., BrainSuite, Medtronic O-arm) allow real-time visualization of lead position relative to the target nucleus before wound closure, enabling immediate repositioning if needed.
DIRECTIONAL STIMULATION AND CLOSED-LOOP DBS (EMERGING TECHNOLOGY): Next-generation directional leads (Abbott Infinity, Boston Scientific Vercise Cartesia HD) allow steering of the electrical field in 3D space, enabling clinicians to capture more STN neurons while avoiding stimulation-induced side effects (e.g., internal capsule activation causing dysarthria, pyramidal symptoms). Closed-loop or adaptive DBS (aDBS) systems — currently in advanced clinical trials — use cortical local field potential (LFP) biomarkers (e.g., beta-band power) recorded from the DBS lead itself to automatically adjust stimulation amplitude in real time, reducing battery drain by 40–50% and improving motor outcomes compared to conventional open-loop DBS. Medtronic's Percept PC with BrainSense technology already offers commercial LFP sensing capability in select markets including India and the UAE.
ANTERIOR THALAMIC NUCLEUS (ANT) DBS FOR EPILEPSY: Patients with drug-resistant focal epilepsy may be candidates for ANT-DBS (as in the SANTE trial), delivered via the same surgical platform but targeting the anterior thalamic nucleus for seizure frequency reduction. This application is available at select epilepsy surgery centers within GAF Healthcare's network.
POST-IMPLANT PROGRAMMING: Initial device activation occurs 2–4 weeks post-implantation, once surgical edema resolves. Comprehensive programming sessions using manufacturer-specific software (Medtronic Neural Navigator, Abbott Clinician Programmer, Boston Scientific's Guided Programming with DirectSense) identify optimal contact configurations and stimulation parameters. Rechargeable IPG systems (particularly recommended for younger or higher-energy patients) require patient-administered charging 30–60 minutes/day but offer 15+ year device longevity versus 3–5 years for primary cell devices.
Cost of Deep Brain Stimulation: India vs. UAE
The cost of Deep Brain Stimulation varies significantly depending on destination, implant manufacturer and model (rechargeable vs. primary cell IPGs cost differently), unilateral vs. bilateral implantation, and the degree of programming follow-up included in the package. India offers internationally comparable surgical expertise at 50–65% lower cost than the UAE, primarily due to lower surgical facility overheads and implant import duty structures, while the UAE provides a premium clinical environment with short-haul access from Europe, the Middle East, and Africa. Both destinations offer FDA/CE-approved implant systems from Medtronic, Abbott, and Boston Scientific. The following estimates represent bilateral DBS (the most common configuration) inclusive of implant hardware, surgical fees, standard hospitalization, and initial programming. They exclude airfare, accommodation, and extended outpatient medication costs.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $14,000 – $22,000 | ~55% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $30,000 – $50,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-TRAVEL EVALUATION (4–8 WEEKS BEFORE DEPARTURE): GAF Healthcare coordinates remote multidisciplinary case review. Patients submit: current neurologist's reports, MRI brain (within 12 months), video of OFF- and ON-medication motor states (for Parkinson's/tremor), complete medication list, and pre-existing comorbidity documentation. The assigned functional neurosurgeon reviews eligibility, requests any outstanding diagnostics, and issues a formal pre-admission acceptance letter required for the e-Medical Visa (India) or UAE Medical Entry process.
PHASE 2 — ARRIVAL AND PRE-OPERATIVE WORKUP (DAYS 1–3): Upon arrival, the patient undergoes structured inpatient or outpatient pre-operative assessment: neuropsychological battery, formal movement disorder neurologist evaluation with video-documented UPDRS scoring, repeat MRI with stereotactic sequences if prior imaging is >6 months old, anesthesia pre-assessment, and medication optimization (levodopa held overnight before the acute challenge test). Implant selection is confirmed (IPG type: rechargeable vs. primary cell; lead type: standard vs. directional) based on patient age, lifestyle, and target indication.
PHASE 3 — STAGE 1 SURGERY: LEAD IMPLANTATION (DAY 3–4): The patient is admitted on Day 3. Under local anesthesia with conscious sedation (awake technique) or general anesthesia (asleep technique), stereotactic frame or robotic arc is applied. Burr holes are created bilaterally (or unilaterally for asymmetric tremor/dystonia). Microelectrode recording confirms STN/GPi neuronal signatures. DBS leads are advanced to target coordinates, macrostimulation performed to assess acute therapeutic effect and exclude side effects, and leads are secured with titanium lead anchors. Postoperative iCT or MRI confirms final lead position and excludes hemorrhage. Patient transferred to neurosurgery ICU/HDU for 24-hour monitoring.
PHASE 4 — STAGE 2 SURGERY: IPG IMPLANTATION (DAY 5–6): Under general anesthesia, the extension cables are tunneled subcutaneously from the burr hole caps, over the mastoid and down the neck, to the infraclavicular IPG pocket. Device connectivity is verified with impedance testing. Typical operative time: 60–90 minutes. Patient discharged to hospital room same evening.
PHASE 5 — INPATIENT RECOVERY AND WOUND CHECK (DAYS 6–8): Wound inspection, suture/staple care, and device integrity checks. Patient and caregiver educated on IPG handling, charging protocol (rechargeable systems), and activity restrictions. Written warning card (MRI compatibility, security screening) issued. Discharge to GAF Healthcare-arranged accommodation.
PHASE 6 — INITIAL PROGRAMMING AND STIMULATION ACTIVATION (DAYS 14–21): First programming session: IPG switched ON, baseline impedances checked, contact survey performed. Initial monopolar review maps therapeutic window (tremor/bradykinesia suppression vs. dysarthria, paresthesia, phosphenes thresholds). Stimulation parameters set conservatively. Medication adjustments (levodopa reduction in STN-DBS patients) initiated.
PHASE 7 — PROGRAMMING OPTIMIZATION AND FIT-TO-FLY CLEARANCE (WEEKS 4–6): A second in-person programming session refines parameters as initial edema resolves and microlesion effect dissipates. Wound is fully healed; sutures/staples removed at Day 10–14. Fit-to-fly medical clearance issued at Week 4–6 after confirmation of: intact wound healing, satisfactory stimulation response, stable neurological status, and — critically — patient/caregiver competency with IPG management. Long-haul flight patients should carry DBS device ID card and airport security letter; full-body metal detectors and millimeter-wave scanners are generally safe; avoid hand-held security wand held over IPG site.
PHASE 8 — REMOTE FOLLOW-UP (MONTHS 3, 6, 12, THEN ANNUALLY): GAF Healthcare facilitates telehealth programming follow-up with the implanting team. For Medtronic Percept PC and Boston Scientific Vercise Genus systems, remote LFP data can be reviewed via cloud-connected clinician portals. Annual IPG battery status checks guide timely replacement surgery planning.
Risks & Considerations
Deep Brain Stimulation carries a well-characterized but meaningful risk profile that every candidate must be counseled on transparently. Hemorrhagic stroke (symptomatic intracranial hemorrhage) occurs in approximately 1–2% of procedures and represents the most feared acute complication, with reported rates of permanent neurological deficit from hemorrhage at 0.5–1%. Infection of the implanted hardware — leads, extensions, or IPG — affects 3–5% of patients and may necessitate full system explantation followed by delayed re-implantation; this risk is mitigated by perioperative antibiotic prophylaxis and strict aseptic surgical technique. Lead migration or fracture requiring revision surgery occurs in 5–15% of patients over the device lifetime. Hardware-related complications including IPG malfunction, lead connector failure, and skin erosion over the device are reported in approximately 10% of patients within 5 years. Stimulation-induced side effects — which are fully adjustable by reprogramming — include dysarthria (particularly with STN stimulation), dyskinesia, mood changes (hypomania with STN-DBS in 4–8% of patients), impaired verbal fluency, and, rarely, acute stimulation-induced depression or suicidality (mandating rigorous pre-implant psychiatric clearance). Cognitive decline is a recognized concern, particularly in patients with pre-existing mild cognitive impairment (MCI); the EARLYSTIM trial and subsequent meta-analyses confirm that appropriately selected patients (normal cognition) do not experience accelerated cognitive decline, but candidates with borderline neuropsychological profiles require individualized risk-benefit analysis. General surgical and anesthesia risks apply as for any intracranial procedure. The rechargeable IPG requires lifelong patient compliance with daily charging; failure to maintain charge risks abrupt stimulation cessation and severe rebound motor symptoms (in dystonia, abrupt DBS cessation can precipitate life-threatening status dystonicus). Finally, DBS does not halt Parkinson's disease neurodegeneration; axial symptoms (gait freezing, falls, dysautonomia, dementia) that are poorly responsive to dopaminergic therapy typically progress despite excellent DBS response, and patients must have realistic long-term expectations established pre-implant.
Top Hospitals for Deep Brain Stimulation
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Apollo Hospitals
New Delhi, India
Fortis Memorial Research Institute
Gurgaon, India
Manipal Hospitals
Bengaluru, India
Manipal Hospitals Dwarka
New Delhi, India
Top Doctors for Deep Brain Stimulation
Internationally trained specialists in Neurology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Anuvrat Sinha
MBBS (with Distinction in Pharmacology), MS (General Surgery), MCh (Neurosurgery)
Neurosurgeon
Artemis Hospital, Gurugram, India
12+ Yearsof experience
Dr. Anuvrat Sinha is a Consultant Neurosurgeon at Artemis Hospital, Gurugram, with over 12 years of medical experience. He specialises in complex brain tumor surgeries — including glioma and meningioma — as well as endoscopic brain procedures, craniotomies, and a wide range of spinal surgeries. Patients and families often describe him as someone who takes the time to explain a difficult diagnosis in plain language, which matters enormously when the stakes… Read more
Dr. Arul K
MBBS, MS, FRCS (Ed) — Fellow of the Royal College of Surgeons of Edinburgh, Neurosurgery Board Certification
Neurosurgeon
Gleneagles HealthCity Chennai, Chennai, India
27+ Yearsof experience
Dr. Arul K is a seasoned neurosurgeon based in Chennai with over 27 years of experience caring for patients with complex brain and spine conditions. Currently serving as Associate Consultant at Gleneagles HealthCity Chennai, he has built a reputation for handling some of the most challenging neurosurgical cases — from skull base tumours and arteriovenous malformations to delicate endoscopic brain procedures. His patients and their families often describe… Read more
Dr. Deepak Arisikere Nataraju
MBBS, MS (General Surgery), M.Ch (Neurosurgery)
Neurosurgeon
Medicover Hospital, Whitefield, Bengaluru, India
20+ Yearsof experience
Dr. Deepak Arisikere Nataraju is a Senior Consultant Neurosurgeon at Medicover Hospitals, Whitefield, Bengaluru, with over two decades of experience in treating complex conditions of the brain, spine, and nervous system. He is widely recognized in the region for his work in minimally invasive spine surgery, endoscopic brain surgery, and skull base procedures — areas where precision and experience make a real difference to patient outcomes. Dr. Deepak… Read more
Dr. Karanjit Singh Narang
M.Ch. (Neurosurgery), M.S. (General Surgery), MBBS
Neurosurgeon
Medanta – The Medicity, Gurugram, India
25+ Yearsof experience
Dr. Karanjit Singh Narang is one of India's most experienced neurosurgeons, serving as Senior Director of Neurosurgery at Medanta – The Medicity in Gurugram. With more than 25 years in the field, he has built a reputation for handling some of the most complex brain and spine conditions — including brain tumors, gliomas, meningiomas, and skull base tumors — using minimally invasive and image-guided techniques that put patient safety first. Dr. Narang… Read more
Dr. Krishna Kumar Choudhary
MS (Surgery), DNB (Neurosurgery), ECFMG Certification, Fellowship in Neurosurgery
Neurosurgeon
Indian Spinal Injuries Centre, New Delhi, India
27+ Yearsof experience
Dr. Krishna Kumar Choudhary is one of India's most experienced neurosurgeons, with over 27 years dedicated entirely to brain and spine surgery. He serves as Director and Chief of Neurosurgery at the Indian Spinal Injuries Centre in New Delhi — a role that reflects both his seniority and the depth of trust his peers and patients place in him. Over the decades, he has built a reputation for taking on complex neurosurgical cases that require not just… Read more
Frequently Asked Questions — Deep Brain Stimulation
The total cost of bilateral Deep Brain Stimulation — encompassing stereotactic neurosurgery in two stages (lead implantation and IPG implantation), the DBS hardware system (Medtronic, Abbott, or Boston Scientific implants), inpatient hospitalization of 5–8 days, anesthesia, ICU/HDU monitoring, neurophysiology (microelectrode recording), and the initial device programming session — ranges from approximately USD 14,000 to USD 22,000 at leading NABH- and JCI-accredited hospitals in India (cities including Delhi, Bengaluru, Chennai, Mumbai, and Hyderabad). The same procedure at JCI-accredited and DHA/DoH-licensed hospitals in Dubai and Abu Dhabi costs between USD 30,000 and USD 50,000, reflecting the higher facility and overhead costs of UAE healthcare infrastructure. This places India at approximately 55–65% less expensive than the UAE for an equivalent procedure using the same FDA/CE-approved implant systems. It is important to note that rechargeable IPGs cost somewhat more upfront than primary cell devices but offer significantly longer battery life (15+ years vs. 3–5 years), potentially avoiding additional replacement surgeries. Unilateral DBS (for asymmetric tremor or dystonia) costs approximately 30–40% less than bilateral in either destination. GAF Healthcare provides itemized, all-inclusive quotations for each patient based on their specific clinical profile, chosen hospital tier, and implant selection prior to commitment.
International patients undergoing Deep Brain Stimulation should plan for a minimum in-country stay of 4–6 weeks. This timeline is dictated by three mandatory clinical milestones: (1) Complete wound healing at all surgical sites — scalp burr hole wounds, the retroauricular tunneling incision, and the infraclavicular IPG pocket — which typically requires 10–14 days and must be fully confirmed before exposure to the cabin pressure changes of long-haul flight; (2) Resolution of the microlesion effect — a transient, edema-related phenomenon after electrode implantation that temporarily improves symptoms independent of stimulation, which lasts 2–6 weeks and can confound early programming; and (3) Completion of at least two formal device programming sessions to establish stable, effective stimulation parameters and demonstrate that the patient is neurologically stable with the device active. For patients with dystonia, stimulation benefit may take several weeks to manifest fully, potentially extending the recommended stay. Patients traveling from long-haul destinations (North America, Australia, Sub-Saharan Africa) are particularly advised to plan for a full 6-week stay. Before boarding, patients should carry their DBS device identification card (mandatory for airport security), a physician letter confirming MRI conditional status of their specific device model, and adequate supply of all medications. GAF Healthcare's medical team issues a formal fit-to-fly certificate at the time of clearance.
The success of DBS is indication-specific and heavily dependent on candidate selection quality — which is why GAF Healthcare insists on rigorous pre-implant multidisciplinary evaluation. For Parkinson's disease, the landmark EARLYSTIM trial (Schuepbach et al., NEJM 2013) demonstrated significantly superior quality of life outcomes with STN-DBS versus best medical therapy in patients with early motor complications. Across large meta-analyses and long-term outcome registries, bilateral STN-DBS achieves a mean 50–60% improvement in UPDRS-III motor scores in the OFF-medication state at 1 year, with 70–80% of appropriately selected patients considered 'responders' by standard outcome criteria. Tremor — both in Parkinson's disease and essential tremor (VIM-DBS) — is among the most robustly responsive targets, with complete or near-complete tremor abolition in 70–90% of essential tremor patients. For dystonia, GPi-DBS achieves 50–70% improvement in BFMDRS (Burke-Fahn-Marsden Dystonia Rating Scale) at 12 months, with primary generalized dystonia responding more robustly than secondary forms. For OCD, the multicenter trial supporting FDA HDE approval demonstrated a 37% mean Y-BOCS improvement, with approximately 60% of patients classified as responders. It must be emphasized that DBS controls symptoms; it does not halt or reverse the underlying neurodegeneration in Parkinson's disease. Axial symptoms — postural instability, freezing of gait, speech, and swallowing difficulties — that are unresponsive to levodopa typically remain unresponsive to DBS. Long-term outcomes are also contingent on the quality of ongoing programming and multidisciplinary follow-up, which GAF Healthcare coordinates through a structured telemedicine program between the implanting team and the patient's home neurologist.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides an end-to-end medical tourism coordination infrastructure that addresses every non-clinical aspect of the DBS journey.
INDIA — VISA AND ENTRY: GAF Healthcare's visa desk prepares and submits the e-Medical Visa application (available to nationals of 156 eligible countries via the Indian government's online portal) on behalf of the patient and up to two accompanying attendants (e-Medical Attendant Visa). The e-Medical Visa grants 60-day stays with triple-entry provision, extendable from within India. Processing typically requires 72–96 business hours. GAF provides the mandatory hospital invitation letter, cost estimate, and appointment confirmation required by the visa authority.
UAE — VISA AND ENTRY: Nationals of over 120 countries enjoy visa-free entry or visa-on-arrival for UAE stays of 30–90 days, making medical travel logistically straightforward. For nationalities requiring advance visas, GAF Healthcare coordinates UAE Medical Visit Visa applications through licensed health authority sponsors. Dubai Health Authority (DHA) and Department of Health Abu Dhabi (DoH) health corridor arrangements also facilitate expedited entry for patients with pre-scheduled clinical appointments.
AIRPORT TRANSFERS AND GROUND LOGISTICS: Dedicated GAF Healthcare ground coordinators meet patients and attendants at arrival airports (Indira Gandhi International Delhi, Kempegowda Bengaluru, Rajiv Gandhi Hyderabad, Chhatrapati Shivaji Mumbai; Dubai International DXB, Abu Dhabi AUH) with identity-verified vehicles. Wheelchair and stretcher transfers are arranged for patients with significant motor disability.
ACCOMMODATION: GAF Healthcare negotiates preferential rates at hospital-adjacent serviced apartments and guest houses for patient attendants — typically 1–2 accompanying family members. Accommodation packages include housekeeping, in-room meals, and Wi-Fi, and are pre-selected for accessibility (elevator access, grab-rail bathrooms) for patients with Parkinson's-related mobility limitations.
INTERPRETATION AND CULTURAL SUPPORT: Certified medical interpreters covering Arabic, Russian, Uzbek, Kazakh, Swahili, French, Bahasa, and other major medical tourism source languages are available in-hospital and on-call for ward rounds, informed consent procedures, and programming sessions. A dedicated GAF patient liaison officer maintains 24/7 WhatsApp and phone availability throughout the inpatient stay.
MEDICAL RECORDS AND CONTINUITY: At discharge, GAF Healthcare compiles a comprehensive medical dossier — including operative reports, intraoperative imaging, device programming parameters, and post-discharge medication plan — formatted for seamless handover to the patient's home neurologist or movement disorder specialist. For DBS systems with remote connectivity (Medtronic Percept PC, Abbott Infinity with myAbbott app), GAF facilitates enrollment in manufacturer remote care programs prior to departure.